Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors

Inclusion criteria

• Age range 18-75 years, open to both male and female participants;
• Participants must meet the following hematologic and hepatic/renal function criteria: Hematology: WBC ≥ 4.0 × 10^9/L or neutrophils ≥ 1.5 × 10^9/L, platelets ≥ 100 × 10^9/L, hemoglobin ≥ 90 g/L; Prothrombin time (PT) or Activated partial thromboplastin time (APTT) ≤ 1.5 times the upper limit of normal (ULN); Hepatic and renal functions: Total bilirubin (T-Bil) ≤ 1.5 times the upper threshold limit (ULT), ALT/AST ≤ 2.5 ULN or ≤ 5 ULT for subjects with liver metastasis, Alkaline phosphatase (ALP) ≤ 2.5 ULN (or ≤ 4.5 ULN in cases of bone or liver metastasis); Blood urea nitrogen (BUN) ≤ 1.5 × ULT, serum creatinine (SCr) ≤ 1.5 × ULT;
• Normal cardiac function;
• Expected survival of at least 12 weeks;
• Good adherence to follow-up;
• Presence of at least one measurable target lesion according to RECIST 1.1 criteria;
• Women of childbearing age (15-49 years) must undergo a pregnancy test within seven days prior to the commencement of the study and test negative; sexually active male and female participants must agree to utilize effective contraception to prevent pregnancy during the study and for three months following the final examination;
• Patients for whom a clinical physician recommends PET/CT scans for the diagnosis and staging of tumors;
• Participants must fully understand and voluntarily agree to participate in the study, and must sign an informed consent form.

Exclusion criteria

• Severe abnormalities in liver and renal function and blood counts;
• Patients planning to conceive;
• Pregnant or lactating women;
• Individuals unable to lie flat for thirty minutes;
• Individuals who refuse to participate in this clinical study;
• Individuals suffering from claustrophobia or other psychiatric disorders;
• Other situations deemed unsuitable for trial participation by the researchers.